Learn more

Published

April 28, 2021

Share

The Chamber and its Global Innovation Policy Center appreciate the opportunity to respond to the European Commission IIA on revision of general pharmaceuticals legislation, consistent with our ongoing support for the Commission’s work to remove trade barriers and protect IP.

Our comments are attached.